Immix Biopharma (IMMX) Competitors $2.15 -0.04 (-1.83%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.18 +0.03 (+1.35%) As of 09/5/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMX vs. TKNO, AVTE, PRQR, ANNX, SOPH, OGI, ENGN, TRDA, CRGX, and LYELShould you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Alpha Teknova (TKNO), Aerovate Therapeutics (AVTE), ProQR Therapeutics (PRQR), Annexon (ANNX), SOPHiA GENETICS (SOPH), Organigram Global (OGI), enGene (ENGN), Entrada Therapeutics (TRDA), CARGO Therapeutics (CRGX), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Immix Biopharma vs. Its Competitors Alpha Teknova Aerovate Therapeutics ProQR Therapeutics Annexon SOPHiA GENETICS Organigram Global enGene Entrada Therapeutics CARGO Therapeutics Lyell Immunopharma Alpha Teknova (NASDAQ:TKNO) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends. Is TKNO or IMMX more profitable? Immix Biopharma has a net margin of 0.00% compared to Alpha Teknova's net margin of -55.24%. Alpha Teknova's return on equity of -26.51% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Alpha Teknova-55.24% -26.51% -18.40% Immix Biopharma N/A -205.35%-110.63% Do analysts rate TKNO or IMMX? Alpha Teknova presently has a consensus target price of $10.00, suggesting a potential upside of 129.36%. Immix Biopharma has a consensus target price of $7.00, suggesting a potential upside of 225.58%. Given Immix Biopharma's higher possible upside, analysts clearly believe Immix Biopharma is more favorable than Alpha Teknova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Teknova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Immix Biopharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals hold more shares of TKNO or IMMX? 13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 12.5% of Alpha Teknova shares are held by company insiders. Comparatively, 55.4% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, TKNO or IMMX? Immix Biopharma has lower revenue, but higher earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlpha Teknova$37.74M6.18-$26.75M-$0.42-10.38Immix BiopharmaN/AN/A-$21.61M-$0.77-2.79 Does the media favor TKNO or IMMX? In the previous week, Immix Biopharma had 1 more articles in the media than Alpha Teknova. MarketBeat recorded 2 mentions for Immix Biopharma and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.24 beat Immix Biopharma's score of 0.91 indicating that Alpha Teknova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Teknova 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, TKNO or IMMX? Alpha Teknova has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. SummaryAlpha Teknova beats Immix Biopharma on 9 of the 15 factors compared between the two stocks. Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMX vs. The Competition Export to ExcelMetricImmix BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.99M$3.17B$5.83B$9.92BDividend YieldN/A2.26%6.70%4.52%P/E Ratio-2.7921.2476.2926.13Price / SalesN/A431.48532.13173.41Price / CashN/A45.7236.9959.28Price / Book4.489.8711.486.09Net Income-$21.61M-$53.42M$3.29B$266.51M7 Day Performance-3.15%2.93%1.28%0.45%1 Month Performance-10.04%11.43%8.56%5.05%1 Year Performance9.14%16.14%61.19%26.03% Immix Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMXImmix Biopharma3.5164 of 5 stars$2.15-1.8%$7.00+225.6%+9.1%$61.99MN/A-2.799Short Interest ↓TKNOAlpha Teknova2.8662 of 5 stars$4.39-3.9%$10.00+127.8%-5.0%$234.91M$37.74M-10.45240Positive NewsAVTEAerovate TherapeuticsN/A$8.03+1.6%N/A-88.3%$232.75MN/A-2.6920News CoveragePositive NewsHigh Trading VolumePRQRProQR Therapeutics2.3411 of 5 stars$2.19-0.7%$8.00+266.1%+32.1%$229.88M$20.46M-4.75180ANNXAnnexon2.4931 of 5 stars$2.09-3.0%$12.50+499.5%-62.3%$229.12MN/A-1.6260News CoveragePositive NewsSOPHSOPHiA GENETICS2.0675 of 5 stars$3.36-0.6%$8.00+138.1%-13.6%$227.07M$65.17M-7.64520News CoverageShort Interest ↑OGIOrganigram Global1.1446 of 5 stars$1.68+1.5%N/A-5.7%$224.53M$117.47M33.51860ENGNenGene2.8943 of 5 stars$4.25-2.5%$23.29+447.9%-21.6%$217.18MN/A-2.5831News CoverageUpcoming EarningsShort Interest ↓TRDAEntrada Therapeutics3.0712 of 5 stars$5.69+1.3%$25.67+351.5%-64.3%$216.24M$79.48M-3.19110News CoveragePositive NewsCRGXCARGO Therapeutics1.6915 of 5 stars$4.47flat$15.40+244.5%N/A$216.17MN/A-0.96116LYELLyell Immunopharma3.4967 of 5 stars$11.23+2.4%$15.00+33.6%-48.1%$215.63M$60K-0.46270News CoveragePositive NewsShort Interest ↓ Related Companies and Tools Related Companies Alpha Teknova Competitors Aerovate Therapeutics Competitors ProQR Therapeutics Competitors Annexon Competitors SOPHiA GENETICS Competitors Organigram Global Competitors enGene Competitors Entrada Therapeutics Competitors CARGO Therapeutics Competitors Lyell Immunopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMX) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
